Neurocrine Biosciences | NBIX - Ativos





Ativos Alterar Data
AbbVie USD 133.96B 62M 2025-12
Acadia Pharmaceuticals USD 1.56B 233.42M 2025-12
Agios Pharmaceuticals USD 1.18B 112.24M 2026-03
ALKERMES USD 2.49B 157.48M 2025-12
Alnylam Pharmaceuticals USD 4.97B 114.67M 2025-12
Amgen USD 90.59B 445M 2025-12
Biogen USD 29.48B 43.6M 2026-03
BioMarin Pharmaceutical USD 7.59B 20.85M 2025-12
Cytokinetics USD 1.42B 12.02M 2025-12
Enanta Pharmaceuticals USD 329.5M 48.77M 2025-12
Exelixis USD 2.84B 20.87M 2025-12
Gilead Sciences USD 59.02B 490M 2025-12
Halozyme Therapeutics USD 2.53B 304.09M 2025-12
Incyte USD 7.34B 381.14M 2026-03
Ionis Pharmaceuticals USD 3.45B 74M 2026-03
Nektar Therapeutics USD 280.41M 20.94M 2025-12
Neurocrine Biosciences USD 4.63B 365.8M 2025-12
Pfizer USD 208.73B 2.64B 2025-09
Prothena USD 326.8M 25.82M 2025-12
Regeneron Pharmaceuticals USD 40.87B 310.1M 2026-03
Repligen USD 2.95B 25.99M 2025-12
Rigel Pharmaceuticals USD 242.53M 35.8M 2025-09
Sarepta Therapeutics USD 3.35B 143.73M 2025-12
Teva Pharmaceutical Industries USD 40.75B 892M 2025-12
Ultragenyx Pharmaceutical USD 1.53B 341.56M 2025-12
Vertex Pharmaceuticals USD 25.64B 780.7M 2025-12
Xoma USD 263.15M 39.7M 2025-09